Articles

Mantle-cell lymphoma is a relatively aggressive type of non-Hodgkin lymphoma. Results from a study of patients who elected to interrupt treatment with ibrutinib plus venetoclax are presented. Read More ›

Targeted drug treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are given indefinitely: either until disease progression or until side effects are no longer manageable. A key question is whether oncologists can use results of minimal residual disease (MRD) testing to determine if patients can take a break from treatment with targeted drugs. Read More ›

Updated analysis of ASCEND trial showed that acalabrutinib, a highly selective Bruton tyrosine kinase inhibitor, improves progression-free survival compared with other treatments for patients with relapsed and refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Read More ›

Now that patients with multiple myeloma are living longer, researchers are focusing more on patients’ quality of life during and after cancer treatment. New research says there’s good news: 1 study found that adding an extra drug to a standard treatment made patients live longer, with no negative impact on their quality of life. Read More ›

Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes. Read More ›

Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant. Read More ›

A study evaluating the safety and efficacy of a new 3-drug combination is underway in patients with relapsed and refractory chronic lymphocytic leukemia (CLL). Read More ›

Results from a study of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to see if treatment with ibrutinib plus venetoclax could be stopped for those who have a good response. Read More ›

Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma. Read More ›

Extended follow-up of the E1912 trial showed a significant advantage for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib + rituximab compared with those treated with fludarabine, cyclophosphamide, and rituximab (FCR). Read More ›